Abstract
The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.
| Original language | English |
|---|---|
| Pages (from-to) | 2153-2160 |
| Number of pages | 8 |
| Journal | Journal of Medical Virology |
| Volume | 80 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2008 |
Fingerprint
Keywords
- Classic Kaposi's sarcoma
- HHV8
- HHV8 subtypes
- Tumor progression
ASJC Scopus subject areas
- Virology
- Infectious Diseases
Cite this
HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. / Mancuso, Roberta; Biffi, Renato; Valli, Marilena; Bellinvia, Monica; Athanasia, Tourlaki; Ferrucci, Silvia; Brambilla, Lucia; Delbue, Serena; Ferrante, Pasquale; Tinelli, Carmine; Clerici, Mario.
In: Journal of Medical Virology, Vol. 80, No. 12, 12.2008, p. 2153-2160.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma
AU - Mancuso, Roberta
AU - Biffi, Renato
AU - Valli, Marilena
AU - Bellinvia, Monica
AU - Athanasia, Tourlaki
AU - Ferrucci, Silvia
AU - Brambilla, Lucia
AU - Delbue, Serena
AU - Ferrante, Pasquale
AU - Tinelli, Carmine
AU - Clerici, Mario
PY - 2008/12
Y1 - 2008/12
N2 - The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.
AB - The link between human herpesvirus 8 (KSHV) and Kaposi's sarcoma (KS) has been proven, but many important aspects including risk factors, genetic predisposition to tumor development, transmission of KSHV, and the pathogenic potential of different genotypes remain to be elucidated. Possible associations between clinical parameters and antibody levels, viral load fluctuations, and viral genotype were analyzed by quantitative real-time PCR, an in-house developed IFA assay, and sequence analysis of ORFK1-VR1 in blood, serum and saliva of 38 subjects with classic KS (cKS). KSHV lytic antibodies were significantly increased in stage IV compared to stage I and II patients (p=0.006 and p=0.041, respectively). KSHV blood, serum, and saliva viral load was comparable in all stages. The highest viral loads were detected in saliva, and they decreased in stages III-IV compared to stages I-II patients. Higher concentrations of lytic antibodies and higher viral loads were observed in fast progressing cKS patients, in whom KSHV detection from blood was also more frequent. Type A KSHV strain was almost exclusively present in rapid progressors (12/17 cases), while C type was mainly present in slow progressing patients (6/7 cases). Finally, detection of type A KSHV strain associated with higher blood viral loads. KSHV lytic antibody levels and viral load can be used to monitor clinical evolution of cKS. Infection supported by KSHV A subtype is associated with more rapid progressive disease. Careful monitoring and aggressive therapeutic protocols should be considered in patients with KSHV A-supported infection.
KW - Classic Kaposi's sarcoma
KW - HHV8
KW - HHV8 subtypes
KW - Tumor progression
UR - http://www.scopus.com/inward/record.url?scp=57349161263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57349161263&partnerID=8YFLogxK
U2 - 10.1002/jmv.21322
DO - 10.1002/jmv.21322
M3 - Article
VL - 80
SP - 2153
EP - 2160
JO - Journal of Medical Virology
JF - Journal of Medical Virology
SN - 0146-6615
IS - 12
ER -